Boardroom Alpha
Meeting calendar
USPH · Annual meeting · Tuesday, May 19, 2026

U S Physical Therapy Inc

7 nominees · 3 ballot items.

Elect seven directors to the Board; a non-binding advisory vote to approve named executive officer compensation (say-on-pay); and ratify Grant Thornton LLP as the company’s independent registered public accounting firm for 2026.

Market cap
$1.1B
1Y TSR
-6.5%
Board grade
B-
Record date
Mar 25, 2026
Filing
DEF 14A
Meeting concluded · May 19, 2026

Follow how the vote landed and what changed on U S Physical Therapy Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.

Proposals

On the ballot3

  1. 1

    Election of Directors

    ManagementBoard: FOR

    Election of seven directors (Christopher J. Reading, Kathleen A. Gilmartin, Dr. Bernard A. Harris, Jr., Michael G. Mayrsohn, Anne B. Motsenbocker, Regg E. Swanson and Peter F. Minan) to serve until the next annual meeting of stockholders.

  2. 2

    Advisory Vote to Approve Named Executive Officer Compensation

    ManagementBoard: FOR

    Non-binding, advisory 'say-on-pay' vote to approve the compensation of the Company’s Named Executive Officers as described in the Proxy Statement.

    More detail

    This management-sponsored, non-binding advisory proposal asks shareholders to approve the Company’s executive compensation program as disclosed in the Proxy Statement, including the Compensation Discussion and Analysis and the related tables and narrative. Management seeks shareholder approval to validate its pay-for-performance framework, which ties a meaningful portion of NEO compensation to Adjusted EBITDA performance ranges and to discretionary subjective goals, and relies heavily on equity awards to align executives with long-term stockholder interests. The Compensation Committee, composed entirely of independent directors and supported by an independent consultant (Meridian), argues the program is market-competitive, features capped annual incentive opportunities, multi-year vesting of equity, a clawback policy, double-trigger change-in-control protections, and newly adopted share ownership guidelines. In 2025 the Company achieved the top of its Adjusted EBITDA performance range ($95.01 million), producing maximum payouts under the objective plans and significant equity grants, which management cites as evidence the incentive structure appropriately rewarded performance. The vote is advisory and non-binding, but the Board will consider the outcome in future compensation decisions; prior shareholder support was strong (approx. 91% in favor at the 2025 meeting), which management cites to justify continuity of its approach. From a governance perspective, shareholders should weigh that a substantial portion of CEO pay is equity-based (creating alignment but concentrating pay in long-term awards), that the CEO remains Chairman (board has a Lead Independent Director), and that disclosed pay ratios are material (CEO-to-median pay ~92.8:1 including equity). Critics could argue that high CEO equity grants and the board’s dual CEO/chair structure warrant closer scrutiny, while proponents will point to objective performance achievement, independent committee oversight, and compensation safeguards as mitigating concerns. Overall, the proposal is framed as a reaffirmation of an established, performance-linked compensation program rather than a request for a change in policy; a 'for' vote supports the Board’s current compensation philosophy while a 'against' vote would signal shareholder dissatisfaction that the Compensation Committee would need to address.

  3. 3

    Ratification of Appointment of Independent Registered Public Accounting Firm

    ManagementBoard: FOR

    Ratification of the appointment of Grant Thornton LLP as the Company’s independent registered public accounting firm to audit the financial statements for the year ending December 31, 2026.

Director elections

Nominees on the ballot7

Independent
Tenure on this board
4.5 yrs
Also a director at
Csw Industrials Inc (CSW)
Ownership

Top institutional holders10

Latest 13F quarter
1BlackRock, Inc.10.6%1,608,348$121M
2BAHL GAYNOR INC5.6%845,388$63M
3Copeland Capital Management, LLC4.6%707,533$53M
4VANGUARD CAPITAL MANAGEMENT LLC4.4%664,062$50M
5STATE STREET CORP4.3%648,387$49M
6KAYNE ANDERSON RUDNICK INVESTMENT MANAGEMENT LLC4.1%627,117$47M
7MORGAN STANLEY3.7%564,110$42M
8DIMENSIONAL FUND ADVISORS LP3.1%473,553$35M
9BANK OF AMERICA CORP /DE/2.9%445,861$33M
10SOUTHERNSUN ASSET MANAGEMENT, LLC2.9%439,904$33M
Filings

Recent key filings

Periodic reports
Definitive proxies
Reference

Frequently asked questions

When is the U S Physical Therapy Inc 2026 annual meeting?
U S Physical Therapy Inc (USPH) holds its 2026 annual shareholder meeting on Tuesday, May 19, 2026.
What is the record date for the U S Physical Therapy Inc 2026 meeting?
The record date for the U S Physical Therapy Inc 2026 meeting is Wednesday, March 25, 2026. Shareholders of record on or before that date are eligible to vote.
Who are the director nominees for U S Physical Therapy Inc's 2026 meeting?
The board is presenting 7 director nominees at the U S Physical Therapy Inc 2026 meeting, listed with their independence status and background.
What proposals will shareholders vote on at the U S Physical Therapy Inc 2026 meeting?
Shareholders will vote on 3 proposals at the U S Physical Therapy Inc 2026 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer